Razieh Heidari

Razieh Heidari

Auto-generated profile, based on publicly available information

Razieh Heidari

Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Journal of Drug Targeting
Verified
Journal Article
Closed access
RHRazieh Heidari
Razieh Heidari
NDNeda Gholamian Dehkordi
Neda Gholamian Dehkordi
RMRoohollah Mohseni
Roohollah Mohseni
MSMohsen Safaei
Mohsen Safaei
Breast cancer is one of the most prevalent and deadliest cancers among women in the world because of its aggressive behavior and inadequate response to conventional therapies. Cellular and gene therapies based on mesenchymal stem cells (MSCs) represent promising treatment strategies for multiple diseases, such as cancers. MSCs are multipotent adult stem cells with important features for cell therapy, such as tissue homing to injured sites, their differentiation potential, their capacity of secreting plenty of trophic factors, and low immunogenicity. The quite easy isolation of these cells from various types of tissues are associated with no ethical concern when dealing with fetal or embryonic stem cells. The MSCs exhibit both pro and anti-oncogenic properties. However, genetic engineering of MSCs and nanoparticles is being employed as a means to solve some of these problems and improve the antitumor properties of these cells. The tumor-homing ability of MSCs and their exosomes to tumor niches have made them as a promising vector for targeted delivery of therapeutic agents to tumors site. The present study investigated MSCs specifications, pro- and anti-oncogenic properties of MSCs in breast cancer, and reviewed targeted breast cancer therapy via engineered MSCs, likely as potent cellular vehicles.

13 February 2023 in IEEE Transactions on Nanobioscience
Verified
Journal Article
Closed access
ZHZahra Rezaei Harandi
Zahra Rezaei Harandi
RHRazieh Heidari
Razieh Heidari
SRSomayeh Reiisi
Somayeh Reiisi
The development nano-carriers based therapeutic methods is a potent strategy for enhancing cellular delivery of drugs and therapeutic efficiency in cancer chemotherapy. In the study, silymarin(SLM) and metformin (Met) were co-loaded into mesoporous silica nanoparticles (MSNs) and evaluated the synergistic inhibitory effect of these natural herbal compound in improving chemotherapeutic efficiency against MCF7MX and MCF7 human breast cancer cells. Nanoparticles have been synthesized and characterized by FTIR, BET, TEM, SEM, and X-ray diffraction. Drug loading capacity and release determined. The both single and combined form of SLM and Met (free and loaded MSN) were used for MTT assay, colony formation and real time-PCR in cellular study. The synthesis MSN were uniformity in size and shape with particle size of approximately 100 nm and pore size of approximately 2 nm. The Met-MSNs IC30, SLM –MSNs IC50 and dual-drug loaded MSNs IC50 were much lower than of free-Met IC30, free-SLM IC50 and free Met-SLM IC50 MCF7MX and MCF7cells. The co-loaded MSNs treated cells were increased sensitivity to mitoxantrone with the inhibition of BCRP mRNA expressions and could induce apoptosis in MCF7MX and MCF7 cells in comparison with other groups. Colony numbers were significantly reduced in comparison to with other groups in the co-loaded MSNs -treated cells (p < 0.01). Our results indicate that Nano-SLM enhances the anti-cancer effects of SLM against human breast cancer cells. The findings of the present study suggest that the anti-cancer effects of both metformin and silymarin enhances against breast cancer cells when MSNs are used as a drug delivery system.

29 January 2025 in BioMed Research International
Verified
Journal Article
Open access
RHRazieh Heidari
Razieh Heidari
VAVahideh Assadollahi
Vahideh Assadollahi
SMSeyedeh Negar Marashi
Seyedeh Negar Marashi
FEFatemeh Elahian
Fatemeh Elahian
SMSeyed Abbas Mirzaei
Seyed Abbas Mirzaei
Long noncoding RNA (lncRNA) plays a critical role in cancer cell proliferation, invasion, metastasis, and chemoresistance. The current study introduces novel lncRNAs in colorectal cancer (CRC) through bioinformatics analysis. GSE134834 CRC‐related microarray of Gene Expression Omnibus (GEO) was analyzed to identify differentially expressed genes (DEGs) in CRC samples against normal samples. Analysis revealed 6763 DEGs ( p < 0.05 and |log fold change (FC)| ≥ 0.5) that include differentially expressed mRNA (DEmRNA) and differentially expressed long noncoding RNA (DElncRNA). Novel lncRNAs were identified, and to better understand the biological function of the identified lncRNAs, gene modules were constructed using weighted gene coexpression network analysis (WGCNA), and finally, two modules for lncRNAs were obtained. The coexpression modules with these lncRNAs were subjected to enrichment analysis in FunRich software to predict their functions through their coexpressed genes. Gene ontology results of modules related to novel lncRNA revealed they significantly enriched the cellular pathways regulation in cancer. The protein–protein interaction (PPI) network of novel lncRNAs‐related modules was constructed using Search Tool for the Retrieval of Interacting Genes (STRING) and visualized using the Cytoscape software. Hub genes were screened from the PPI network by the CytoHubba plug‐in of Cytoscape. The hub genes were MRTO4 , CDK1 , CDC20 , RPF2 , NOP58 , NIFK , GTPBP4 , BUB1 , BUB1B , and BOP1 for the lightpink4 module and BYSL , RPS23 (ribosomal protein S23), RSL1D1 (ribosomal L1 domain containing 1), NAT10 , NOP14 , GNL2 , MRPS12 , NOL6 (nucleolar protein 6), IMP4 , and RRP12 (ribosomal RNA processing 12 homolog) for the pink module. The expression levels of the top DEmRNA and module hub genes in CRC were validated using the Gene Expression Profiling Interactive Analysis (GEPIA) database. Generally, our findings offer crucial insight into the hub genes and novel lncRNAs in the development of CRC by bioinformatics analysis, information that may prove useful in the identification of new biomarkers and treatment targets in CRC; however, more experimental investigation is required to validate the findings of the present study.

8 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FKFatemeh Karimzadeh
Fatemeh Karimzadeh
RHRazieh Heidari
Razieh Heidari
FLFatemeh Mahmoudi Lamooki
Fatemeh Mahmoudi Lamooki
ESEhsan Heidari Soureshjani
Ehsan Heidari Soureshjani
Shahkaar AzizShahkaar Aziz
Shahkaar Aziz
SMSeyed Abbas Mirzaei
Seyed Abbas Mirzaei
The increasing prevalence of gastrointestinal infections caused by Cryptosporidium parvum and Schistosoma mansoni, coupled with the lack of definitive treatments, underscores the need for vaccine development to prevent infection-related cancers. Using experimentally validated epitopes for vaccine development enhances confidence in inducing strong and durable immune responses compared to predicted epitopes, which require lab validation. In this study, we employed a unique computational strategy using 197 experimentally validated epitopes of C. parvum and S. mansoni obtained from the IEDB database. After applying homology filters against human proteome and microbiome sequences and conducting HLA population coverage analysis, we chose seven cytotoxic T lymphocyte (CTL), seven helper T cell (HTL), and five B-cell epitopes. These were combined with an RpfE adjuvant and appropriate linkers to design a highly immunogenic chimeric antigen with broad global coverage, optimized for stability, solubility, and manufacturability. Molecular docking revealed strong binding affinities of CTL and HTL epitopes to their respective HLA alleles. Immune simulations demonstrated the multi-epitope antigen’s ability to elicit both innate and adaptive immune responses. Docking of the vaccine construct with immune receptors (TLR2-TLR1 and TLR4-MD2) yielded significant scores of − 179.8 ± 4.5 and − 191.5 ± 3.4 kcal/mol, respectively. Molecular dynamics simulations verified the structural stability of vaccine–receptor complexes, while binding free energy calculations reinforced their strong affinities. Finally, in silico cloning validated the vaccine’s potential for efficient E. coli expression. These computational findings support the construct as a promising vaccine candidate against C. parvum and S. mansoni, warranting further experimental validation.

7 January 2025 in Cancer Reports
Verified
Journal Article
Open access
RHRazieh Heidari
Razieh Heidari
VAVahideh Assadollahi
Vahideh Assadollahi
SMSeyedeh Negar Marashi
Seyedeh Negar Marashi
FEFatemeh Elahian
Fatemeh Elahian
SMSeyed Abbas Mirzaei
Seyed Abbas Mirzaei
Background: Bioinformatics analysis of hepatocellular carcinoma (HCC) expression profiles can aid in understanding its molecular mechanisms and identifying new targets for diagnosis and treatment.Aim: In this study, we analyzed expression profile datasets and miRNA expression profiles related to HCC from the GEO using R software to detect differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRs).Methods and results: Common DEGs were identified, and a PPI network was constructed using the STRING database and Cytoscape software to identify hub genes. The reduced levels of tumor suppressor miRNAs or down regulated DEmiRs may be increased levels of oncogenes, the oncomirs or up regulated DEmiRs may be decreased levels of tumor suppressor genes in cancerous cells. According to this strategy, increased and decreased DEGs, also increased and decreased DEmiRs were selected. The multimir package was employed to predict target genes for DEmiRs then DEmiRs‐hub gene network created. We identified approximately 1000 overlapping DEGs and 60 DEmiRs. Hub genes included RRM2, MELK, KIF11, KIF23, NCAPG, DLGAP5, BUB1B, AURKB, CCNB1, KIF20A, CCNA2, TTK, PBK, TOP2A, CDK1, MAD2L1, BIRC5, ASPM, CDCA8, and CENPF, all associated with significantly worse survival in HCC. miR‐224, miR‐24, miR‐182, miRNA‐1‐3p, miR‐30a, miR‐27a, and miR‐214 were identified as important DEmiRs with targeting more than six hub genes.Conclusion: Generally, our findings offer insight into the interaction of hub genes and miRNAs in the development of HCC by bioinformatics analysis, information that may prove useful in identifying biomarkers and therapeutic targets in HCC.

8 July 2025 in Scientific Reports
Verified
Journal Article
Open access
RHRazieh Heidari
Razieh Heidari
EGElham Gholami
Elham Gholami
AZAzita Alasvand Zarasvand
Azita Alasvand Zarasvand
SMSeyed Abbas Mirzaei
Seyed Abbas Mirzaei
MGMohammadreza Gholami
Mohammadreza Gholami
VAVahideh Assadollahi
Vahideh Assadollahi
Methotrexate (MTX) is used to treat malignant and autoimmune disorders, while it also hurts testicular tissue leading to infertility. It has been shown that MTX induces testicular injury by producing oxidative stress, inflammatory cytokines, and apoptotic cascades, but its molecular mechanisms have not been fully investigated. Selenium (Se) with antioxidant properties is protective in testicular germ cells. The use of Se to modulate the oxidative stress caused by MTX was investigated in this study, focusing on P38 and NF-κB pathways in the testis of NMRI mice treated models with MTX. The control, MTX, Se, and MTX + Se groups were considered the male mice in this study. RNA extraction was utilized to examine the P38 and NF-κB gene expression by Real-time quantitative polymerase chain reaction (RT-qPCR). The testicular protein samples were extracted to analyze the protein expression of P38 and NF-κB. The assessment of TNF-α, IL-1β, and IL-6 levels was examined using ELISA. Tukey's tests and ANOVA were used for statistical analysis (p < 0.05). The increased significantly of P38 and NF-κB mRNA expression and up-regulation of P38 and NF-κB proteins were observed in the group treated with MTX compared to the control group while the administration of Se caused a significant decrease in the mRNA or proteins expression. The TNF-α, IL-6 and IL-1β protein expression in the following MTX treatment, in testis tissue, was raised significantly, and co-treatment with Se significantly reduced the testis tissue level of TNF-α, IL-6 and IL-1β protein in contrast to that of the MTX group. Our findings show the potential of Se as a medicine to modulate the destructive effects of MTX in testicular tissue which suggests Se supplementation as a viable method to prevent testicular damage from chemotherapy and maintain male fertility.